Today is another memorable day for Leecan! Leecan first self-developed inhalation suspension product, Budesonide Suspension for Inhalation, has been approved for production, with the drug approval number: H20244102, and the trade name: Baichang Zhisu. At the same time, Salbutamol Sulfate Solution for Inhalation was also approved, with the drug approval number: H20244093 and the trade name: Baichang Ruihe. After Terbutaline Sulfate Nebulised Inhalation Solution, it is the second and third product approved by Leecan. 
Since its establishment in May 2021, Leecan Pharmaceuticals, under the leadership of all leaders and the joint efforts of all staff, has taken ‘science and technology to improve the quality of life’ as its noble mission, and is committed to making Chinese people's own advanced inhalation preparations and complicated preparations through technological breakthroughs and innovation to make every minute of every patient's life full of dignity and love. The sweat and hard work of all the staff of Leecan Pharmaceuticals have finally been rewarded today!
Thanks to the hard work and unremitting efforts of the Leecan Pharmaceuticals staff, this achievement and joy belong to all the staff of Leecan Pharmaceuticals! At the same time, Leecan Pharmaceuticals has come to a new starting point to meet new challenges. Approved products will be rapidly put into commercial production at the base of Nanjing and then marketed and sold to patients as quickly as possible. As always, Leecan Pharmaceuticals will adhere to high standards and strict requirements with high product quality to provide the market with “reassure us, patients, and the community” of high-quality drugs, to win the reputation of patients with the quality of Leecan Pharmaceuticals and establish the brand of Leecan!
Let's continue to work hard to harvest more fruits and witness more miracles of Leecan! Leecan will be successful!
025-58181716
Share:
